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Abstract: Actinic keratoses (AKs) are epidermal cutaneous neoplasia observed predominantly 
in middle-aged and older subjects with mainly photo type I and photo type II on sun-exposed 
surfaces as a result of DNA damage. AKs have historically been characterized as being “pre-
cancerous”; however, now it is considered by many authors a carcinoma in situ that can persist 
or progress to invasive squamous cell carcinoma (SCC) with metastatic potential. Despite the 
advances in the recognition of typical clinic, dermoscopic and histologic patterns, currently it 
is not yet possible to predict which AKs will progress to SCC. For this reason, early diagnosis 
and effective therapy are recommended based on cost/risk/benefit analysis. Current treatment 
consists of lesion-directed or field-directed therapies or a combination of both. Among the 
topical field therapies, ingenol mebutate stands out for its therapeutic efficacy, both as directed 
lesion therapy and as field directed therapy. The aim of this review is to demonstrate the utility 
of ingenol mebutate in the management of AK in daily clinical practice and to highlight data 
from real world in order to confirm evidence from pivotal studies. In order to explore clinical 
data from real world, PubMed searches were performed with the search terms “clinical data 
ingenol mebutate” and “real world ingenol mebutate”. The hits were examined for relevant 
articles using defaults criteria. The timeframe for the sample search started from the first pub-
lication on this topic in 2008 up to now. A total of 23 articles were found using the keywords 
specified above. The overview points out a low number of real-life studies on the effectiveness 
and tolerability of this novel treatment due to short period of clinical experience for its recent 
approval. Further real-life studies are required in order to better identify the efficacy, safety and 
adherence of the drug on a larger population.
Keywords: ingenol mebutate, actinic keratosis, field cancerization, real world, photodamage, 
novel treatment
Introduction
Actinic keratoses (AKs) are common epidermal cutaneous neoplasia that are observed 
predominantly in middle-aged and older subjects with mainly photo type I and photo 
type II on sun-exposed surfaces as a result of DNA damage due to cumulative dose 
of UV radiation absorbed during life. They represent one of the clinical signs of skin 
photoaging, which is most often characterized by actinic lentigines (sunspots) or 
wrinkles.1 Over the last decades, the incidence of AK has continuously increased. It has 
an approximate prevalence of 79% in men and 68% in women aged between 60 and 
69 years.2 The prevalence is highest in regions with high UV exposure, especially in 
Australia, where the prevalence rate among middle-aged adults (.40 years old) ranges 
from 40% to 60%.3 Based on recent data of an Italian multicentric study (24 general 
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dermatology clinics) conducted between December 2014 and 
February 2015, AK prevalence in patients aged $30 years 
was 27.4%; 34.3% in men and 20% in women. More than 
half of patients had 1–5 AK lesions, and over three quarters 
had face or neck lesions.4
The major risk factors of developing AKs are photo 
type I and II, male sex, advanced age, freckles, high lifetime 
sun exposure, history of pediatric solar erythema and use 
of some potentially photosensitizing drugs (thiazide diuret-
ics, amiodarone and diltiazem). Furthermore, in patients 
undergoing immunosuppressive treatments, the risk has 
increased significantly, as well as the risk of developing 
invasive and metastatic forms of squamous cell carcinoma 
(SCC).5
Clinically, AK usually presents as erythematous, scaly 
patch or papule varying in size from a few millimeters to 
1–2 cm, covered by slight desquamation or dry and adherent 
scales on an erythematous base.1,6 AKs are usually multiple 
and are most commonly localized on the face, ears, neck, 
bald scalp, extensor surface of the extremities and lower 
lip. There are some clinical variants of AK: hyperkeratotic 
form, which occurs more frequently as a firm infiltrated 
papule, covered by a keratotic scale rough on palpation; the 
pigmented form, similar to a solar lentigo; the skin horn, 
characterized by hyperkeratotic conic protuberance. Actinic 
cheilitis is the term used for AKs appearing on the lips, 
usually formed by the confluence of several AKs involving 
the lower lip.
AKs are asymptomatic, although some patients report 
itching, burning or a splinter-like sensation in the affected 
skin area.
In addition to these visible lesions, there are invisible 
subclinical AKs that are estimated to occur up to ten times 
more often than visible AKs. These lesions arise on an area 
of photo-damaged skin called field cancerization.1
Sometimes, clinical aspects are unsatisfactory for cor-
rect diagnosis of AK. In these cases of uncertain diagnosis, 
dermoscopy is a very useful method with high sensitivity 
and specificity (98.7% and 95%, respectively) for the diag-
nosis of AK.7
Histologically, AKs have traditionally been categorized 
as KIN I or AK I if focal atypia of basal keratinocytes 
involves only the lower third of the epidermis, KIN II/AK II 
if atypia affects the lower two thirds of the epidermis or 
KIN III/AK III if the atypical cells extend also to the upper 
layers.8 The alterations described previously are not limited 
to skin lesions visible to clinical observation and dermoscopic 
examination but they occur in photo-damaged skin area 
known as field cancerization, in which there are genetically 
altered cells but histologically free of atypia that are flanked 
by malignant cells.9
AKs have historically been considered as “precancer-
ous” or “premalignant” as these lesions are confined to 
the epidermis without metastatic potential.10 Many authors 
have affirmed that these lesions are pre-cancerous epithelial 
tumors potentially developing into SCC.11–13 Nevertheless, 
this hypothesis is in contrast to the evidence that AK shares 
histopathologic criteria, genetic tumor markers and identical 
p53 gene mutations with SCC.
The visible clinical lesions are recognized as the initial 
manifestation of a multi-step carcinogenesis process or 
disease continuum that can progress from initial subclinical 
keratinocyte dysplasia into invasive SCC.14
Recent studies have showed that AKs with atypical cells 
present only in the basal layers (classified as AK I) are the 
most common precursors of invasive squamous cell carci-
noma (iSCC) of the skin. Due to the presence of atypia in 
the basal layer as well as the risk of progression to invasive 
cancer, AK is considered now by many authors as a carci-
noma in situ that can persist or progress to iSCC.
About the actual risk for an individual AK development 
to invasive SCC, several studies14,15 have highlighted that 
approximately 8% of all AKs progress into invasive SCCs. 
Other data report that in a patient with ten AKs, the risk of 
malignant progression is 9.6%, while in a patient with seven 
to eight AKs, the risk is 6%–10% over a 10-year period.16
The risk of AK evolving into SCC is increased in males 
and individuals with photo type I and II, a family history 
of skin cancer and a human papillomavirus infection or in 
immune-suppressed individuals (being at a risk increased 
by 250).6
Despite the advances in the recognition of typical clinical, 
dermoscopic and histologic patterns, currently it is not yet 
possible to predict which AK will progress to SCC.17
For this reason, prevention, early diagnosis and effec-
tive treatment are recommended based on cost/risk/benefit 
analysis.
Current treatment consists of a multitude of lesion-
directed or field-directed therapies or a combination of both. 
The therapy choice is influenced by several factors, such as 
number of lesions, natural history of lesions, localization 
and extension of the disease, patient’s age, comorbidity 
and immunosuppression, personal history of previous skin 
lesions, previous treatments of AKs and personal preferences 
of the patient and physician. Lesion-directed treatment is 
usually a first-line approach for isolated lesions, while a field-
directed approach is used when multiple lesions are present.6 
The goals of field therapy are to remove clinically visible as 
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well as subclinical lesions and to prevent the development 
of invasive SCC. Patients with multiple lesions (lesion field) 
or with a history of multiple lesions should benefit from a 
topical treatment with diclofenac 3% gel, ingenol mebutate 
gel, imiquimod cream, photodynamic therapy with aminole-
vulinic acid or methyl aminolevulinate or 5-fluorouracil 5% 
cream.17 The aim of this review is to demonstrate the utility of 
ingenol mebutate in the management of AK in daily clinical 
practice and to point out data from the real world in order to 
confirm evidence from pivotal studies.
Review of literature
Pharmacology, mode of action, 
pharmacokinetics, dosing and 
administration of ingenol mebutate
Ingenol mebutate (ingenol-3-angelate, previously PEP005) 
is a novel topical chemotherapy field-directed therapy for 
AK, which was approved by the Food and Drug Adminis-
tration in January 2012.18 It is a hydrophobic, macrocyclic 
diterpene ester extracted from an active fraction of the sap 
of a non-invasive weed Euphorbia peplus,19 a plant that has 
traditionally been used as a home treatment for various skin 
diseases, including AK and basal cell carcinomas.20
The therapeutic effect of ingenol mebutate has been 
partially explained with a dual mechanism of action; it 
induces rapid (1–2 hours after application) cell death in 
transformed keratinocytes through disruption of plasma 
membrane and subsequent mitochondrial swelling and, 
within days, stimulates neutrophil-mediated form of 
antibody-dependent cytotoxicity that eliminates residual 
tumor cells.21
Ingenol mebutate is an agonist of intracellular pro-
tein kinase C (PKC), which is involved in the signaling 
pathways of different physiologic functions, such as cell 
proliferation, differentiation and senescence, cell sur-
vival/death, invasion and angiogenesis.22 The activation 
of the pro-apoptotic intracellular PKC induces apoptosis 
of dysplastic keratinocytes, whereas keratinocytes with 
normal differentiation are resistant to the PKC mediated 
pro-apoptotic effects.23 The activation of PKC/MEK/ERK 
pathway results also in immunostimulatory effects with 
an infiltration of neutrophils into the area of application 
and antibody production that stimulates cytotoxic T cells 
against dysplastic cells.24
Ingenol mebutate is a substrate for P-glycoprotein. After 
topical application, it passes the stratum corneum barrier 
through P-glycoprotein absorptive drug transport and exerts 
its action in the dermis and hypodermis where it causes 
vascular damage.19,25 The systemic absorption from the skin 
is minimal.26 Ingenol mebutate and its metabolites have been 
shown to have no effect on the cytochrome P450 (CYP) 
enzyme system.27
Ingenol mebutate, formulated as a propyl alcohol-based 
gel for topical use,28 is available in two different concen-
trations. The 0.015% gel formulation is divided into three 
monodoses for three consecutive days of application on the 
face and scalp, whereas the 0.05% gel formulation is divided 
into two monodoses for two-day treatment of the trunk or 
extremities.23,29 Every monodose is sufficient to treat a field 
area of 25 cm2.
Quality of life, patient satisfaction and 
adherence to treatment
Generally, the therapy is well tolerated. Due to its mecha-
nism of action, the most common adverse events are the 
application-site conditions such as erythema, pruritus, 
flaking/scaling/dryness, erosions and scabbing/crusting.30 
These local skin responses are dose related and tend to 
spontaneous resolution within one month after treatment 
without sequelae.19 The severity of these adverse reactions 
is correlated with the initial damage within the affected skin 
field.31 (Figures 1 and 2).
Results of Phase II and Phase III studies have demon-
strated that ingenol mebutate gel was effective and well 
Figure 1 Clinical aspects at baseline, during and after ingenol mebutate treatment in a 65-year-old man.
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tolerated by patients, with reduction until disappearance 
of clinically visible AKs and resolution of lesion over one 
year.24,32,33 Greater improvements were reported in face/scalp 
compared with trunk/extremities.34
In 2015, Jubert-Esteve et al conducted a pilot study in 
Spain to evaluate quality of life (QoL) and side effects in 
patients affected by AKs receiving treatment with ingenol 
mebutate. This study observed that QoL improved after 
treatment and that it depended on a subjective patient scale. 
Moreover, side effects affected neither QoL nor patients’ 
satisfaction with treatment, maybe because of their short 
duration and easiness of application.35
Evidence from randomized controlled trial (RCT) showed 
extremely high adherence rates (over 95%) in patients receiv-
ing ingenol, as well as improvement of patients’ QoL.33,35 
Recently, Ricci et al showed real-life efficacy and safety of 
ingenol mebutate, demonstrating that the majority of patients 
(82%) considered the treatment more convenient compared 
to other therapeutic options.36
Clinical data from real world
In order to explore clinical data from real world about this 
novel treatment for AKs, PubMed searches were performed 
with the search terms “clinical data ingenol mebutate” and 
“real world ingenol mebutate”. The hits were examined for 
relevant articles using defaults criteria. The timeframe for 
the sample search started from the first publication on this 
topic in 2008 up to March 2018. Articles were classed as 
relevant if ingenol mebutate was studied to treat AK in real 
world, and an effect was reported with sex/site/AK number 
or grade/previous treatment differences.
A total of 23 articles were found using the abovemen-
tioned keywords. Two of them were excluded from these 
reviews as they do not treat skin carcinomas but colon cancer 
cells,37 or expression of human hepatic drug transporter.38
One study has not been considered because it describes 
only the mechanism of action of the drug without clinical 
evidence.39 Furthermore, all trial-based articles were 
excluded.40–46
Two other articles have the aim to develop therapeutic 
algorithms for AK that can be used in everyday clinical 
practice in a real-world context, but they are also based on 
clinical trials. In the first article, an international panel of 
14 experts on AK proposed a therapeutic approach to AK that 
can be used in real-life setting starting from data derived from 
clinical trials and authors’ practical clinical experience. The 
authors specify that in 2017 there was not enough published 
information related to the real-life practice and therefore 
recommendations are based on consensus of their practical 
clinical experience.47
In the second work, Drèno et al proposed AK treatment 
algorithm for daily practice in France but they evaluated 
ingenol mebutate’s efficacy through pooled analysis of 
previous trials.48
Most recent paper regarding real-world data on ingenol 
mebutate has been written by Norrlid et al. Real-world 
Swedish and Danish patients have been studied to obtain 
patient-reported outcomes in topical field treatment. The 
results show higher patient satisfaction with ingenol mebu-
tate treatment compared with diclofenac (P=0.006) and a 
higher treatment adherence for ingenol mebutate compared 
to both diclofenac (P,0.001) and imiquimod (P=0.007), 
most likely due to a reduced treatment duration. Local skin 
reactions (LSRs) were less common in patients treated with 
diclofenac compared to imiquimod group (P,0.001) or 
ingenol mebutate group (P,0.001) and less common with 
imiquimod group compared to ingenol mebutate group 
(P=0.015). A limitation of this study is that the data are 
only based on patient’s self perception, lacking in clinician’s 
objective evaluation.49
The most interesting paper on efficacy and safety in real-
life use of ingenol mebutate for the treatment of AK was 
published by Ricci et al. They enrolled 88 patients during the 
study period (April 2014–April 2015) with multiple AKs of 
Figure 2 Clinical aspects at baseline, during and after ingenol mebutate treatment in a 71-year-old woman.
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the face and scalp. Real-life lesion clearance rate of AKs on 
the scalp was found to be higher in this study compared to 
previous RCTs33 (80% vs 53%) and clearance rate for AKs 
located on the face was similar to previous RCT reports33 
(82% vs 78%). AK on the scalp was higher in the study 
compared to previous RCTs33 (80% vs 53%). At one-week 
follow-up, patients with photo type I–II showed stronger local 
site reactions, like erythema and skin erosions than patients 
with higher photo type. Furthermore, patients with residual 
local site reaction at eighth week of follow-up would seem 
to show reduced clinical outcomes. Real clinical significance 
should be better evaluated. Authors point out the differences 
in the number of lesions for field in RCTs compared to real-
life studies (4–8 vs .9 lesions) and the difficulty of correct 
evaluation of patient adherence to therapy in the context of 
an RCT.36
In 2016, a retrospective cohort study was performed in 
order to evaluate factors influencing response to ingenol mebu-
tate therapy for AK of the face and scalp. In total, 130 patients 
were enrolled and efficacy was evaluated comparing clinical 
and dermoscopic features collected at baseline and at each 
control visit (days 2, 3, 8, 15, 29 and 57). All the patients 
completed the three applications of ingenol mebutate 0.015% 
gel; 101 subjects (77.7%) underwent face treatment and 29 
(22.3%) underwent scalp treatment. Regarding efficacy, the 
great majority of study population (119, 91.5%) reached at 
least a 75% clearance of AKs, in particular 58 patients (44.6%) 
achieved a complete response and 61 (46.9%) a partial one; 
poor responders were 11 (8.5%). LSRs were evaluated at each 
control visit. Ingenol mebutate 0.015% gel was found to be 
independently related to both the head site and the level of 
LSR, demonstrating a higher efficacy on AKs localized on 
the face and in those with more severe LSRs. Considering 
reported data, ingenol mebutate treatment seems to be more 
effective on the face than on the scalp and the efficacy seems 
to be directly related to the level of LSR.50
Sometimes real-word use of ingenol mebutate is not 
limited to the treatment of classically defined AK. Grandi 
et al described a single-center experience in the treatment 
of “hydroxyurea-induced squamous dysplasia” (HISD) with 
ingenol mebutate.51 Hydroxyurea is an antimetabolite drug 
used in the treatment of chronic myelogenous leukemia, 
polycythemia rubra vera, myeloproliferative disorders and 
sickle cell anemia. In 2004, Sanchez-Palacios and Guitart 
used the term “hydroxyurea-induced squamous dysplasia” to 
identify a drug-induced non-melanoma skin cancer (NMSC) 
with a synergistic carcinogenic action between chronic sun 
exposure and drugs. This statement justifies the use of the 
same therapies for both NMSC and drug-induced NMSC.52 
Five patients with HISD on the face or scalp or trunk or 
extremities were treated with a cycle of ingenol mebutate 
at both concentrations (150 μg/g or 500 μg/g) depending 
on lesion localization. At 57 days of follow-up, the authors 
reported an overall response rate of 87.5%, a reduction of 
78.0% of total lesions compared to time 0 (P,0.01), in 
absence of severe adverse event (grade 3–4).51
At last, Athanasakis et al performed a cost-effectiveness 
analysis of ingenol mebutate (IM) versus other topical alter-
natives for the treatment of AK in Greece, concluding that 
IM could be the most cost-effective first-line topical field 
treatment option.53
Conclusion
Over the last decades, the incidence of AK has continuously 
increased.6 Although previously AKs were considered as 
precancerous lesions, to date greater evidence consider it as 
a carcinoma in situ that can persist or progress to iSCC with 
metastatic potential. Furthermore, in addition to these visible 
lesions, there are invisible subclinical AKs that are estimated 
to occur up to 10 times more often than visible AKs. These 
lesions arise to a large extent in photo-damaged skin area 
called field cancerization.1 To date, there are no defined and 
reliable clinical predictors that identify an AK that could be 
transformed into iSCC. This recent evidence demands an 
early diagnosis and an effective treatment based on cost/
risk/benefit analysis.1,17
Current treatment consists of a multitude of lesion-
directed or field-directed therapies or a combination of 
both. In patients with multiple lesions (lesion field) or with 
a history of multiple lesions, field therapy is preferred.6 The 
goals of field therapy are to remove clinically visible as well 
as subclinical lesions and to prevent the development of 
iSCC. Among the topical field therapies, ingenol mebutate, 
a novel topical chemotherapy, stands out for its short treat-
ment course and efficacy, both as directed lesion therapy and 
field directed therapy. After topical application, it passes the 
stratum corneum barrier and exerts its action in the dermis 
and hypodermis with a minimal systemic absorption, which 
is effective and well tolerated by patients.33
The overview points out a low number of real-life studies 
on the effectiveness and tolerability of ingenol mebutate 
due to its recent approval and consequently short period of 
clinical experience. Real-life studies are essential to translate 
the RCT results to clinical practice; therefore, further real-life 
studies are required to better identify the efficacy, safety and 
adherence of the drug in a larger population.
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